Singular Genomics Systems, Inc. (OMIC)
NASDAQ: OMIC · Real-Time Price · USD
21.68
+0.16 (0.74%)
Nov 20, 2024, 4:00 PM EST - Market closed
Singular Genomics Systems Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Revenue | 2.67 | 2.91 | 0.77 | - | - | - |
Revenue Growth (YoY) | 2.77% | 280.52% | - | - | - | - |
Cost of Revenue | 4.02 | 3.47 | 0.79 | - | - | - |
Gross Profit | -1.35 | -0.56 | -0.02 | - | - | - |
Selling, General & Admin | 46.27 | 52.58 | 47.26 | 28.62 | 6.29 | 2.29 |
Research & Development | 43.48 | 47.76 | 46.2 | 32.66 | 21.25 | 10.48 |
Operating Expenses | 89.75 | 100.34 | 93.46 | 61.28 | 27.53 | 12.77 |
Operating Income | -91.1 | -100.9 | -93.49 | -61.28 | -27.53 | -12.77 |
Interest Expense | -1.14 | -1.1 | -0.76 | -0.85 | -0.72 | -0.02 |
Interest & Investment Income | 7.83 | 9.08 | 3.37 | 0.73 | 0.46 | 0.41 |
Other Non Operating Income (Expenses) | - | - | - | -2.18 | -0.16 | 0.05 |
EBT Excluding Unusual Items | -84.42 | -92.92 | -90.88 | -63.57 | -27.95 | -12.33 |
Gain (Loss) on Sale of Investments | - | - | - | - | - | 0.01 |
Asset Writedown | -1.9 | -1.9 | - | - | - | - |
Other Unusual Items | - | - | - | -35.2 | - | - |
Pretax Income | -86.32 | -94.82 | -90.88 | -98.77 | -27.95 | -12.32 |
Net Income | -86.32 | -94.82 | -90.88 | -98.77 | -27.95 | -12.32 |
Net Income to Common | -86.32 | -94.82 | -90.88 | -98.77 | -27.95 | -12.32 |
Shares Outstanding (Basic) | 2 | 2 | 2 | 2 | 0 | 0 |
Shares Outstanding (Diluted) | 2 | 2 | 2 | 2 | 0 | 0 |
Shares Change (YoY) | 3.35% | 2.32% | 51.30% | 344.62% | 22.69% | - |
EPS (Basic) | -34.77 | -39.08 | -38.32 | -63.01 | -79.27 | -42.89 |
EPS (Diluted) | -34.77 | -39.08 | -38.40 | -63.01 | -79.27 | -42.89 |
Free Cash Flow | -80.86 | -74.62 | -93.12 | -56.57 | -26.25 | -12.2 |
Free Cash Flow Per Share | -32.57 | -30.75 | -39.26 | -36.09 | -74.47 | -42.46 |
Gross Margin | -50.77% | -19.17% | -3.14% | - | - | - |
Operating Margin | -3415.97% | -3466.20% | -12220.52% | - | - | - |
Profit Margin | -3236.67% | -3257.30% | -11879.61% | - | - | - |
Free Cash Flow Margin | -3031.72% | -2563.28% | -12172.03% | - | - | - |
EBITDA | -86.98 | -97.39 | -91.06 | -60.15 | -26.9 | -12.42 |
D&A For EBITDA | 4.13 | 3.51 | 2.43 | 1.13 | 0.64 | 0.35 |
EBIT | -91.1 | -100.9 | -93.49 | -61.28 | -27.53 | -12.77 |
Source: S&P Capital IQ. Standard template.
Financial Sources.